SUPPLEMENTARY TABLES

Table of Contents

S	JPPLEMENTARY TABLES35	
	Supplementary Table 1. Search strategy used to identify relevant systematic reviews and meta-analyses on the association between time to cancer diagnosis and treatment and outcomes of interest	
	Supplementary Table 2. Characteristics of systematic reviews on the association between time to cancer diagnosis and treatment and clinical outcomes	.[
	Supplementary Table 3. Characteristics of included meta-analyses on the association between time to cancer diagnosis and treatment and cli	linical

Supplementary Table 1. Search strategy used to identify relevant systematic reviews and meta-analyses on the association between time to cancer diagnosis and treatment and outcomes of interest

Search term	Search	Keywords/MeSH terms
	number	
Cancer	1	'neoplasm'/exp OR (Neoplasms) OR (Cancer) OR (Cancers) OR (Neoplasm)
		OR (Tumors) OR (Tumor) OR (Malignancy) OR (Malignancies) OR (Malignant Neoplasms)
		OR (Malignant Neoplasm) OR (Neoplasm Benign)
Diagnosis & Treatment	2	(Diagnosis) OR (diagnose) OR (treat) OR (treatment) OR (therapy) OR (care) OR (screen) OR
		(surgery) OR (radiation therapy) OR (systemic therapy) OR (chemotherapy) OR (adjuvant
		chemotherapy) OR (adjuvant radiotherapy) OR (neoadjuvant chemotherapy) OR (neoadjuvant
		radiotherapy)
Exposure	3	(delay) OR (wait time) or (postpone) OR (interval) OR (deferred) OR (deferral) OR (time to
		surgery) OR (time to treatment) OR (waiting period) OR (patient delay) OR (provider delay)
		OR (doctor delay) OR (time to treatment initiation) OR (system delay) OR (doctor delay) OR
		(professional delay) OR (time interval) OR (postponement) OR (time to diagnosis)
Outcome	4	(outcomes) OR (recurrence) OR (survival) OR (mortality) OR (tumour progression) OR
		(postoperative complications) OR (oncologic outcomes) OR (disease free survival) OR (overall
		survival) OR (pathological complete response) OR (recurrence free survival) OR (local
		recurrence) OR (metastasis) OR (progression free survival)
Study type	5	(systematic review) OR (meta-analysis) OR (metanalyses) OR (systematic reviews)
Aggregation of search terms	6	1 AND 2 AND 3 AND 4 AND 5
Limits	7	Limit 6 to yr="2010-2019"

The search was performed on 15 February 2021, limiting to publications from before the COVID-19 pandemic (1 January 2010 - 31 December 2019), with no restriction on publication language.

Supplementary Table 2. Characteristics of included systematic reviews on the association between time to cancer diagnosis and treatment and clinical outcomes

First author (year)	Databases searched	Number of hits	Number of included studies	Total Number of participants	Countries in which studies were conducted
Brasme (2012) (28)	EMBASE, Science Citation Index, Google Scholar	6,412	98	22,619	Not reported
van den Bergh (2013) (24)	PubMed and EMBASE	4,950	17	34,517	Not reported
Doubeni (2018) (30)	MEDLINE	4,979	8	77,035	Canada, France, USA
Foster (2013) (26)	MEDLINE, EMBASE	2,111	16	2,628	Not reported
Lethaby (2013) (29)	Medline, EMBASE, EMBASE Classic, Centre for Reviews and Dissemination databases, Cochrane Library, Medline In-Process, Other Non-Indexed Citations	1,665	32	11,016	France, Denmark, Israel, UK, Japan, Switzerland, Germany, Canada, USA, China, Brazil, Belgium, Italy, Hong Kong, Singapore, Turkey, South Africa, Nigeria, Sweden
Neal (2015) (20)	MEDLINE, MEDLINE in-process, EMBASE, Cumulative Index to Nursing and Allied Health Literature, PsychINFO, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, Health Technology Assessment Database, NHS Economic Evaluation database.	193,077	117	401,706	UK, Italy, Spain, Netherlands, Denmark, Finland, France, Norway, Switzerland, Sweden, Germany, Poland, Austria, Belgium, Romania, Greece, Denmark, India, Japan, China, Hong Kong, Malaysia, South Korea, USA, Canada, Brazil, Turkey, Israel, Australia, New Zealand, Saudi Arabia, Libya, South Africa
Graboyes (2018) (23)	PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library	Not reported	5	Not reported	Netherlands, USA, Canada, South Korea
Hansen (2018) (22)	PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library	3,259	5	13,514	Denmark, USA, Canada, South Korea
Mattosinho (2019) (27)	PubMed/MEDLINE, Literatura Latino- Americana e do Caribe em Ciências da Saúde, Scientific Electronic Library Online	434	9	1,560	Brazil, Honduras, Chile, Argentina, Pero, México
Warren (2019) (25)	PubMed, EMBASE, MEDLINE	575	10	30,298	Not reported

Supplementary Table 3. Characteristics of, and subgroup and/or sensitivity analysis reported by included meta-analyses on the association between time to cancer diagnosis and treatment and clinical outcomes

First	Databases searched	Number		Total	Subgroup and/	or Sensitivity analyses	<u>-</u>	Countries in which studies were conducted								
author (year)		of hits		number of participants	Covariate	Response variable of interest	Pooled risk estimate [95% CI] (model type, heterogeneity statistics I ² or Ri)									
Gomez (2009) (37)	MEDLINE, EMBASE, and ISI proceedings	Not reported	9	1,895	Cancer type	TNM (Oral)	OR:1.47 [1.09–1.99] (fixed-effects) OR:1.55 [0.96–2.51] (random-effects, Ri = 0.55)	USA, Israel, Canada, Finland,								
						TNM (Oral delay >1 month)	OR:1.69 [1.26–2.77] (fixed-effects) OR:1.41 [0.73–2.75] (random-effects, Ri = 0.80)	Greece, Thailand, Japan, Brazil,								
					Study Quality	TNM (High-quality)	OR: 1.40 [1.11–1.76] (fixed-effects) OR: 1.31 [0.83–2.07] (random-effects, Ri= 0.74)	UK								
						TNM (low-quality)	OR: 1.01 [0.62–1.65] OR: 1.14 [0.48–2.74] (random-effects, Ri= 0.39)									
					Follow-up period	TNM (≥ 10 year)	OR: 1.40 [1.11–1.76] OR: 1.31 [0.83–2.07] (random-effects, Ri=0.74)	-								
														TNM (< 10 year)	OR: 1.01 [0.62–1.65] OR: 1.14 [0.48–2.74] (random-effects, Ri= 0.67)	-
					Stratification by site	TNM (Yes)	OR: 1.51 [1.19–1.90] OR: 1.47 [0.93–2.32] (random-effects, Ri= 0.73)	-								
						TNM (No)	OR: 0.85 [0.55–1.31] OR: 0.93 [0.49–1.79] (random-effects, Ri= 0.54)	-								
					Confounding adjustment (tobacco smoking, alcohol consumption)	TNM (Yes)	OR: 1.06 [0.83–1.35] OR: 1.02 [0.72–1.43] (random-effects, Ri= 0.46)	-								
						TNM (No)	OR: 2.26 [1.54–3.32] OR: 2.13 [0.97–4.67] (random-effects, Ri= 0.74)	-								
Des Guetz (2010)	PubMed	42	42 11	17,645	Excluding the 2 largest studies	Mortality	RR:1.14 [1.04–1.25]	Not reported								
(43)			betv		Cut-off delays between surgery and AC	Mortality	RR:1.18 [1.13–1.23]									
						Mortality (Colon)	HR: 1.25 [1.17-1.34]									

					Studies on Colon cancer	Mortality (Stage III colon)	HR: 1.25 [1.18-1.33]	
Biagi (2011) (44)	MEDLINE, EMBASE, Cochrane Database of Systematic	198	10	15,410	Excluding the 2 largest studies	Mortality	HR: 1.15 [1.10-1.22]	Not reported
	Reviews, Cochrane Central Register of Controlled Trials					Mortality	HR: 1.13 [1.10-1.17]	
					Excluding the 3 largest studies	Cancer-specific survival	HR: 1.15 [1.10-1.19]	
Seoane	MEDLINE, EMBASE,	1,016	10	1,286	Cancer type	Mortality (oral cancer)	RR: 1.00 [0.92-1.10] (fixed-effects)	Finland,
(2012) (19)	ISI Proceedings						RR: 1.27 [0.81–1.98] (random-effects, Ri = 0.94)	Spain, USA, Denmark
						Mortality (pharynx	RR: 1.68 [1.22-2.31] (fixed-effects)	
						cancer)	RR: 1.69 [1.05–2.72] (random-effects, Ri = 0.55)	
						Mortality (larynx cancer)	RR: 1.05 [1.02-1.08] (fixed-effects)	
							RR: 1.64 [0.91–2.96] (random-effects, Ri = 1.00)	
					Percentage of	Mortality (≥ 60%)	RR: 1.74 [1.30-2.33] (fixed-effects)	_
					cases in stage	Wortainty (2 00 70)	RR: 1.76 [1.21–2.54] (random-effects,	
					III and IV		Ri = 0.37)	
						Mortality (<60%)	RR: 1.04 [1.01-1.07] (fixed-effects)	
							RR: 1.19 [0.99–1.44] (random-effects, Ri = 0.96)	
					Study design	Mortality (retrospective)	RR: 1.09 [1.00-1.19] (fixed-effects)	
							RR: 1.57 [1.11–2.24] (random-effects, Ri = 0.92)	
						Mortality (partially	RR: 1.04 [1.01-1.07] (fixed-effects)	
						prospective)	RR: 1.34 [0.69–2.61] (random-effects, Ri = 1.00)	
					Primary care	Mortality	RR: 1.50 [1.25-1.79] (fixed-effects)	
					centres		RR: 1.77 [1.14–2.73] (random-effects, Ri = 0.81)	_
					Questionnaires	Mortality	RR: 1.04 [1.01-1.07] (fixed-effects)	
							RR: 1.04 [0.95–1.13] (random-effects,	
					Church	Manhalih, /v	Ri = 0.84)	_
					Study participants	Mortality (population- based)	RR: 1.02 [0.92-1.11] (fixed-effects)	
					participarits	baseu)	RR: 1.16 [0.82–1.65] (random-effects, Ri = 0.89)	
						Mortality (hospital-	RR: 1.05 [1.02-1.08] (fixed-effects)	
						based)	RR: 1.67 [1.14–2.44] (random-effects, Ri = 0.99)	
							Mortality	RR: 1.09 [1.00-1.19] (fixed-effects)

					Source of mortality data unknown		RR: 1.68 [1.13–2.49] (random-effects, Ri = 0.94)	
				Source of data unknown	Mortality	RR: 1.04 [1.01-1.07] (fixed-effects)	1	
							RR: 1.17 [0.85–1.60] (random-effects, Ri = 0.99)	1
					Adjusted for Sex	Mortality (yes)	RR: 1.04 [1.01-1.07] (fixed-effects) RR: 1.16 [0.99–1.36] (random-effects,	- -
						Mantality (a.s.)	Ri = 0.94)	_
						Mortality (no)	RR: 2.77 [1.81-4.24] (fixed-effects) RR: 2.77 [1.81-4.24] (random-effects,	-
							Ri = 0.00)	
					Study quality	Mortality (study quality score ≥4)	RR: 1.54 [1.28-1.86] (fixed-effects) RR: 1.77 [1.14–2.75] (random-effects,	-
							Ri = 0.81)	
						Mortality (study quality score <4)	RR: 1.04 [1.012-1.07] (fixed-effects) RR: 1.04 [0.93–1.17] (random-effects,	-
							Ri = 0.89)	
Yu (2013)	PubMed, EMBASE, Cochrane Library,	1,157	7	34,097	Stepwise exclusion	Mortality (1 study) Mortality (2 studies)	HR: 1.17 [1.12-1.22] HR: 1.23 [1.12-1.34]	Italy, France, Denmark,
(40)	Web of Science					,		USA
Seoane (2015) (18)	MEDLINE, EMBASE, Web of Science	653	10	1,023	Study quality	TNM, T1, T2, T4, or T11, high quality	RR: 2.44 [1.36–4.36] (fixed-effects) RR: 2.44 [1.36–4.36] (random-effects, Ri = 0.00)	Canada, Thailand, Finland, Netherlands,
						TNM, T1, T2, T4, or T11, low quality	RR: 1.53 [1.26–1.86] (fixed-effects)	UK, Argentina, Spain
							RR: 1.53 [1.12–2.08] (random-effects, Ri = 0.55)	1
Wang	PubMed, Cochrane	3,053	15	4,431	Time interval	pCR rate (5 weeks)	RR: 0.67 [0.40-1.12]	Not reported
(2015) (33)	Library, EMBASE					pCR rate (6 weeks)	RR: 1.03 [0.76-1.42]	
						pCR rate (7 weeks)	RR: 1.45 [1.18-1.78]	-
						pCR rate (8 weeks) pCR rate (10 weeks)	RR: 1.49 [1.15-1.92] RR: 0.83 [0.65-1.06]	-
						pCR rate (12 weeks)	RR: 0.81 [0.60-1.08]	-
Gupta	MEDLINE, EMBASE,	Not	11	79,616 (of	Treatment	LR (sequencing)	RR: 1.08 [0.98-1.19] (fixed-effects)	Not reported
(2016) (31)	Cochrane Register of Controlled Trials	reported		the 34 studies)	sequencing vs non- sequencing	LR (non-sequencing)	RR: 1.08 [1.01-1.15] (fixed-effects)	- Not reported
					studies	Mortality (sequencing)	RR: 1.0 [0.94-1.06] (fixed-effects)	
						Mortality (non- sequencing)	RR: 0.98 [0.87-1.10] (fixed-effects)	
						LR	RR: 1.07 [1.03-1.10]	

					Inclusion of all studies regardless of quality	Mortality	RR: 1.06 [1.04-1.07]	
Petrelli (2016) (34)	PubMed, EMBASE, Web of Science, Cochrane Library	5,065	13	3,584				Not reported
Raphael (2016)	ael MEDLINE, EMBASE	1,326	14	56,269	Study type	Mortality (RCT)	RR: 1.06 [0.97-1.16] (random effects)	Denmark, Italy, France,
(41)						Mortality (institution- based cohort study)	RR: 1.20 [1.00-1.44] (random effects)	Canada, US, England, New
						Mortality (population- based cohort study)	RR: 1.43 [1.43-1.69] (random effects)	Zealand
					Validity	Worsened DFS (high validity only)	RR: 1.04 [1.00-1.08]	-
						Worsened DFS (not high validity)	RR: 1.06 [0.97-1.15]	
						Worsened DFS (high validity)	RR: 1.06 [0.99 -1.12] (random effects)	
						Worsened DFS (not high validity)	RR: 1.06 [0.97 -1.15] (random effects)	
Du	PubMed, EMBASE, and Cochrane Library	1,914	1,914 13	19,652	Stepwise exclusion	pCR	RR: 1.25 [1.16-1.35]	Not reported
(2017) (36)							RR: 1.25 [1.16-1.35]	
(30)							RR: 1.31 [1.07-1.60]	
							RR: 1.25 [1.16-1.35]	
							RR: 1.26 [1.16-1.36]	
							RR: 1.27 [1.17-1.37]	
							RR: 1.25 [1.16-1.35]	
							RR: 1.25 [1.16-1.36]	
							RR: 1.25 [1.16-1.35]	1
							RR: 1.25 [1.15-1.35]	
							RR: 1.24 [1.15-1.35]	
							RR: 1.26 [1.17-1.36]	
					Waiting interval	pCR (7-weeks)	RR: 1.51 [1.20-1.89]	1
Lin (2017) (38)	MEDLINE, EMBASE, Clinical Trials, Cochrane Central Register of Controlled Trials.	2,622	5	1,016	Stepwise exclusion	2-year OS, 5-year OS, pCR, postoperative mortality, anastomotic leakage		Italy, USA, Taiwan, France

Liu (2017) (46)	PubMed, Web of Science	5,277	14	59,569	Study design	Mortality (prospective) (Categorical lag-time variable) Mortality (retrospective) (Categorical lag-time	HR: 1.22 [1.02-1.46] (random-effects, I ² = 48.7%) HR: 1.08 [1.01-1.15] (random-effects, I ² = 0%)	(Continent only provided) Asia, North America, Europe
					Residual disease	variable) Mortality (Asia) (Categorical lag-time variable)	HR: 1.06 [0.80-1.38] (random-effects, I ² = NA)	_
						Mortality (North America) (Categorical lag-time variable)	HR: 1.11 [0.94-1.32] (random-effects, I ² = 87.7%)	
				_		Mortality (Europe) (Categorical lag-time variable)	HR: 1.25 [1.05-1.29] (random- effects, I ² = 21.6%)	
		Number of cases (Cate varia Mort. (Cate varia) Residual Mort. (Cate varia) Chemotherapy Mort. (Plat (Cate varia) Mort. (Plat Taxa (Cate varia) Mort. (Plat Taxa (Cate varia) Mort. (All) (Cate varia) Mort. (III-I)				Mortality (<600) (Categorical lag-time variable)	HR: 1.16 [0.83-1.62] (random-effects, I ² = 60.6%)	
						Mortality (≥600) (Categorical lag-time variable)	HR: 1.15 [1.02-1.29] (randomeffects, l ² = 77.6%)	
						Mortality (Yes) (Categorical lag-time variable)	HR: 0.69 [0.30-1.60] (random-effects, I ² = NA)	
				Chem		Mortality (No) (Categorical lag-time variable)	HR: 1.35 [0.51-3.57] (random-effects, I ² = NA)	
					Chemotherapy	Mortality (Platinum-based) (Categorical lag-time variable)	HR: 1.26 [0.98-1.63] (random-effects, I ² = 7.8%)	
			Mortality (Platinum-based plus Taxane) (Categorical lag-time variable)	HR: 1.17 [1.04-1.32] (random-effects, I ² = 65.9%)				
					FIGO stage	Mortality (All) (Categorical lag-time variable)	HR: 1.09 [0.93-1.28] (random-effects, I ² = 0%)	
				FIGO stage	1 100 Stage	Mortality (III–IV) (Categorical lag-time variable)	HR: 1.23 [1.07-1.42] (random- effects, I ² = 81.5%)	

	1	T
	Mortality (I–II) (Categorical lag-time variable)	HR: 0.78 [0.51-1.19] (random-effects,
Adjustment for FIGO staging	Mortality (Yes) (Categorical lag-time variable)	HR: 1.16 [1.04-1.30] (random- effects, I ² = 70.9%)
as potential confounder	Mortality (No) (Categorical lag-time variable)	HR: 0.92 [0.48-1.77] (random-effects, I ² = NA)
Adjustment for histology as a	Mortality (Yes) (Categorical lag-time variable)	HR: 1.07 [0.91-1.26] (random-effects, I ² = 36.7%)
potential confounder	Mortality (No) (Categorical lag-time variable)	HR: 1.26 [1.19-1.34] (random- effects, I ² = 0%)
Adjustment for residual disease as a	Mortality (Yes) (Categorical lag-time variable)	HR: 1.22 [1.10-1.36] (random- effects, I ² = 23.5%)
potential confounder	Mortality (No) (Categorical lag-time variable)	HR: 1.09 [0.89-1.34] (random-effects, I ² = 62.6%)
Study design	Mortality (prospective) (Continuous lag-time variable)	HR: 1.06 [1.00-1.12] (random- effects, I ² = 0%)
	Mortality (retrospective) (Continuous lag-time variable)	HR: 1.04 [0.97-1.13] (random-effects, I ² = 69.1%)
Geographic location	Mortality (Asia) (Continuous lag-time variable)	HR: 1.15 [1.04-1.27] (random- effects, I ² = NA)
	Mortality (North America) (Continuous lag-time variable)	HR: 1.01 [1.00-1.02] (random- effects, I ² = 0%)
Number of	Mortality (Europe) (Continuous lag-time variable) Mortality (<600)	HR: 1.06 [1.00-1.12] (random- effects, I ² = 0%) HR: 1.07 [1.00-1.15] (random-
cases	Wortanty (~000)	effects, I ² = 44.2%)

		I (0)	1
		(Continuous lag-time	
		variable) Mortality (≥600)	HR: 1.01 [1.0-1.02] (random-effects,
		(Continuous lag-time	$ 1^2 = 55.8\% $
		variable)	1 - 55.676)
	Residual	Mortality (Yes)	HR: 1.09 [1.01-1.78] (random-
	disease	(Continuous lag-time	effects, I ² = 0%)
	GIOCAGE	variable)	0.100.05, 1 = 0.707
		Mortality (No)	HR: 0.98 [0.94-1.03] (random-effects,
		(Continuous lag-time	
		variable)	
	Chemotherapy	Mortality	HR: 1.00 [0.90-1.11] (random-effects,
		(Platinum-based)	$I^2 = NA$
		(Continuous lag-time	,
		variable)	
		Mortality	HR: 1.02 [0.99-1.05] (random-effects,
		(Platinum-based plus	I ² = 26.2%)
		Taxane)	
		(Continuous lag-time	
		variable)	
		Mortality (NA)	HR: 1.15 [1.04-1.27] (random-
		(Continuous lag-time	effects, I ² = NA)
		variable)	LID: 4.00 [0.00 4.44] (readers offers
		Mortality (All) (Continuous lag-time	HR: 1.03 [0.93-1.14] (random-effects,
		variable)	
	FIGO stage	Mortality (III–IV)	HR: 1.05 [0.99-1.11] (random-effects,
		(Continuous lag-time	$1^2 = 66.4\%$)
		variable)	. – 55.170)
		Mortality	HR: 1.05 [0.99-1.11] (random-effects,
		(Yes)	
	Adjustment for	(Continuous lag-time	, , , , , , , , , , , , , , , , , , ,
	FIGO staging	variable)	
	as potential	Mortality	HR: 1.03 [0.93-1.14] (random-effects,
	confounder	(No)	$I^2 = NA$
		(Continuous lag-time	
		variable)	
		Mortality	HR: 1.02 [0.99-1.05] (random-effects,
		(Yes)	I ² = 26.2%)
	Adjustment for	(Continuous lag-time	
	histology as a potential	variable)	HD 4 07 50 04 4 001 / " :
		Mortality	HR: 1.07 [0.94-1.23] (random-effects,
	confounder	(No)	I ² = 72.0%)
		(Continuous lag-time variable)	
	Adjustment for	Mortality	HR: 1.07 [1.00-1.15] (random-
	residual	(Yes)	effects, I ² = NA)

Loureiro	PubMed/MEDLINE,	1,369	12	5,212	disease as a potential confounder	(Continuous lag-time variable) Mortality (No) (Continuous lag-time variable) Mortality	HR: 1.04 [0.98-1.09] (random-effects, I ² = 54.6%)	Spain,
(2017) (39)	EMBASE, Thomson Reuters, Web of Science Core Collection, ASTRO and ESTRO proceedings of annual meetings (2000-2013)				studies without WT to RT period restrictions	,		Canada, Brazil, USA, Germany
Usón (2017) (45)	PubMed	239	12	12,056	Stepwise exclusion	Mortality, 3-year	OR: 1.17 [1.05-1.29] (fixed-effects)	Not reported
Zhan (2017) (42)	PubMed, EMBASE, Web of Science, Cochrane library, ASCO meeting abstracts	2,390	12	78,462	Excluding the largest 2 studies	Mortality	HR: 1.10 [1.08-1.12] (random- effects, I ² = 43.5%)	Italy, France, Denmark, USA, UK,
					Publication year	Mortality (1999)	HR: 2.15 [1.2-3.85] (random-effects, I ² = %NA)	China
						Mortality (2005)	HR: 0.00 [0.02-1.05] (random-effects, I ² = 0%)	
						Mortality (2006)	HR: 1.22 [1.11-1.34] (random- effects, I ² = 0%)	
						Mortality (2013)	HR: 1.08 [1.06-1.10] (random- effects, I ² = NA)	
						Mortality (2014)	HR: 1.10 [1.06-1.15] (random- effects, I ² = 0%)	
						Mortality (2015)	HR: 1.32 [1.23-1.41] (random- effects, I ² = 0%)	
						Mortality (2016)	HR: 1.13 [1.08-1.19] (random- effects, I ² = 0%)	
					Excluding the largest study	Worsened DFS	HR: 1.09 [1.03-1.14]	
Wu (2018) (32)	PubMed, EMBASE, MEDLINE, Cochrane Library	897	5	1,244				Not reported
Petrelli (2019) (35)	MEDLINE, EMBASE, Cochrane Library	8,752	34	141,853				Canada, US, Sweden, Netherlands, UK, Brazil, Korea, Denmark, Taiwan, Italy, Japan, China

Zhao (2019) (21)	PubMed, EMBASE, Medline, Cochrane, ClinicalTrials.gov	258	8	885	Treatment type	Disease progression (Melphalan- prednisone) Disease progression	RR: 0.22 [0.08-0.64] (random- effects, I ² = 59%) RR: 1.00 [0.83-1.21] (random-effects,	Not reported
						(bisphosphonate)	$ 1^2 = 0\%$	
						Disease progression (immunomodulatory drug	RR: 0.43 [0.31-0.59] (random- effects, l ² = 0%)	
						Disease progression (Monoclonal antibody)	RR: 0.87 [0.36-2.07] (random-effects, I ² = NA)	
					Treatment type	Mortality (Melphalan- prednisone)	RR: 1.05 [0.82-1.35] (fixed-effects, I ² = 37%)	
						Mortality (bisphosphonate)	RR: 0.76 [0.18-3.29] (fixed-effects, I ² = NA)	
						Mortality (immunomodulatory drug)	RR: 0.63 [0.38-1.04] (fixed-effects, I ² = 34%)	
						Mortality (Monoclonal antibody)	RR: 0.73 [0.17-3.08] (fixed-effects, l ² = 33%)	
					High-risk SMM	Disease progression	RR: 0.51[0.37-0.70] (fixed-effects, l ² = 47%)	
					High-risk SMM	Mortality	RR: 0.53 [0.29-0.97] (fixed-effects, I ² = 0%)	

AC, adjuvant chemotherapy; CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; LR, local recurrence; OR, odds ratio; OS, overall survival; pCR, pathological complete response; RCT, randomized controlled trial; RR, risk ratio; SMM, smoldering multiple myeloma

Significant pooled risk estimates are bolded.

^{--,} indicate that subgroup and/or sensitivity analyses were not conducted or were not available.